Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.


Company’s activities

Mabion S.A. is focused on conducting research and development activities which enable the implementation of new biotechnological and biosimilar drugs developed thanks to the achievements of modern genetic engineering. The Company’s strategic goal is to develop, manufacture and market drugs used in treatment of cancer, autoimmune and metabolic diseases. The Company is currently developing several drugs which are biosimilar to original medicinal products (so–called reference drugs) available on the market, which are used in the treatment of cancer, autoimmune and metabolic diseases.

These include:

  • monoclonal antibody MabionCD20 – an oncology drug biosimilar to MabTher/Rituxan (where the active substance is rituximab) manufactured by Roche. MabThera/Rituxan is widely used in the treatment of blood cancers (lymphomas, leukaemia) and rheumatoid arthritis;
  • monoclonal antibody MabionHER2 – an oncology drug biosimilar to Herceptin (where the active substance is trastuzumab) manufactured by Roche. Herceptin is used in breast cancer treatment;
  • monoclonal antibody MabionVEGF_Fab – a drug biosimilar to Lucentis (where the active substance is Ranimizumab). Lucentis (Roche) is used in adults in several diseases resulting in vision impairment;
  • monoclonal antibody MabionEGFR – an oncology drug biosimilar to Erbitux (where the active substance is Cetuximab). Erbitux (Imcolne) is indicated in metastatic colorectal cancer treatment;
  • monoclonal antibody MabionVEGF – an oncology drug biosimilar to Avastin (where the active substance is Bevacizumab). Avastin (Genetech/Roche) is used in adults in cancer treatment (colon or rectal cancer, metastatic breast cancer, metastatic or recurrent lung cancer) along with other anticancer drugs.

MabionCD20 is the top priority drug which is currently also at the most advanced stage of development among all drugs produced by the Company.


© Mabion S.A. all rights reserved Polityka Prywatności